|InSite Vision Incorporated|
965 Atlantic Avenue
United States - Map
InSite Vision Incorporated, an ophthalmic product development company, develops ophthalmic pharmaceutical products to address unmet eye care needs in the United States. It is developing products based on its proprietary DuraSite drug delivery technology. The companys lead products comprise AzaSite, a macrolide antibiotic for the treatment of bacterial conjunctivitis; and Besivance, a fluoroquinolone antibiotic for the treatment of bacterial conjunctivitis. Its products also include ISV-101, a formulation with a low concentration of bromfenac for the treatment of dry eye disease. In addition, the company is involved in preparing a new drug application for the commercial approval of BromSite by the U.S. Food & Drug Administration for the prevention of pain and inflammation associated with ocular surgery; and advancing AzaSite Plus and DexaSite through Phase III clinical studies for the treatment of eye infections. Further, it has a pipeline of earlier-stage product candidates based on its platform technologies. The company has collaborative, licensing, and service agreements with Pfizer and Pfizer Products, Inc.; Akorn Pharmaceuticals; Catalent Pharma Solutions; and Bausch and Lomb Incorporated. InSite Vision Incorporated was founded in 1986 and is based in Alameda, California.
|Mr. Timothy Ruane M.B.A.,
Chief Exec. Officer, Director and Member of Officer Equity Grant Committee
|Mr. Louis C. Drapeau B.S., M.B.A.,
Chief Financial Officer, Principal Accounting Officer, VP and Member of Officer Equity Grant Committee
|Mr. Surendra I. Patel ,
VP of Operations and Quality
|Dr. Lyle M. Bowman Ph.D.,
VP of Devel. and Sec.
|Dr. Kamran Hosseini M.D., Ph.D.,
Chief Medical Officer, VP of Clinical Affairs, VP of Clinical & Regulatory Affairs and Member of Scientific Advisory Board
|Amounts are as of Dec 31, 2013 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year.|
|Currency in USD.|